93 related articles for article (PubMed ID: 27308605)
1. hMENA(11a), a hMENA isoform sending survival signals.
Trono P; Di Modugno F; Nisticò P
Mol Cell Oncol; 2016 Mar; 3(2):e1083648. PubMed ID: 27308605
[TBL] [Abstract][Full Text] [Related]
2. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
4. The cooperation between hMena overexpression and HER2 signalling in breast cancer.
Di Modugno F; Mottolese M; DeMonte L; Trono P; Balsamo M; Conidi A; Melucci E; Terrenato I; Belleudi F; Torrisi MR; Alessio M; Santoni A; Nisticò P
PLoS One; 2010 Dec; 5(12):e15852. PubMed ID: 21209853
[TBL] [Abstract][Full Text] [Related]
5. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
[TBL] [Abstract][Full Text] [Related]
6. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
[TBL] [Abstract][Full Text] [Related]
7. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
8. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
9. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
[TBL] [Abstract][Full Text] [Related]
10. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
11. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
[TBL] [Abstract][Full Text] [Related]
12. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
[TBL] [Abstract][Full Text] [Related]
13. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-induced TGF-β-RBFOX2-ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer.
Ahuja N; Ashok C; Natua S; Pant D; Cherian A; Pandkar MR; Yadav P; Vishnu NSS; Mishra J; Samaiya A; Shukla S
NAR Cancer; 2020 Sep; 2(3):zcaa021. PubMed ID: 33089214
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
Toyoda A; Kawana H; Azuhata K; Yu J; Omata A; Kishi H; Higashi M; Harigaya K
Int J Oncol; 2009 Jan; 34(1):53-60. PubMed ID: 19082477
[TBL] [Abstract][Full Text] [Related]
18. Enabled homolog shown to be a potential biomarker and prognostic indicator for breast cancer by bioinformatics analysis.
Li QL; Su YL; Zeng M; Shen WX
Clin Invest Med; 2019 Jan; 41(4):E186-E195. PubMed ID: 30737978
[TBL] [Abstract][Full Text] [Related]
19. The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior.
Balsamo M; Mondal C; Carmona G; McClain LM; Riquelme DN; Tadros J; Ma D; Vasile E; Condeelis JS; Lauffenburger DA; Gertler FB
Sci Rep; 2016 Oct; 6():35298. PubMed ID: 27748415
[TBL] [Abstract][Full Text] [Related]
20. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]